– Martina Molsbergen, VP, Business Development, Crucell; Barbara Yanni, Chief Licensing Officer, Merck & Co.; David Colpman, Senior VP, Business Development, Shire Pharmaceuticals; and Joern-Peter Halle, Head, Early-Stage Licensing, Merck Serono, a division of Merck KGaA

Previous articleElias A. Zerhouni to Step Down as Director of the NIH
Next articleClarient Allys with Definiens for Image Analysis Tools for Use in Cancer Diagnostics